ASCO 2020

REVIEW UroToday

Viewing 1-20 of 133 articles

ASCO 2020: Genitourinary Cancers Highlights – Kidney and Bladder

ASCO 2020: A Phase II Study of M6620 in Combination with Carboplatin Compared with Docetaxel in Combination with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

ASCO 2020: Evaluation of a Mainstream Model of Genetic Testing for Men with Prostate Cancer

ASCO 2020: Genitourinary Cancers Highlights – Prostate, Testicular, and Penile Cancers

ASCO 2020: Short-Term Adjuvant Versus Neoadjuvant Hormone Therapy in Localized Prostate Cancer: A Pooled Individual Patient Analysis of Two Phase III Trials

ASCO 2020: Checkpoint Inhibition in Metastatic Urothelial Carcinoma: Timing is Everything

ASCO 2020: PDIGREE: An Adaptive Phase III Trial of PD-Inhibitor Nivolumab and Ipilimumab with VEGF TKI Cabozantinib in Metastatic Untreated Renal Cell Cancer (Alliance A031704)

ASCO 2020: CYCLONE 2: A Phase II, Randomized, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or Without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer

ASCO 2020: Quality of Life for the Treatment Sequence of Abiraterone Acetate plus Prednisone Followed by Enzalutamide Versus the Opposite Sequence for Metastatic Castration-Resistant Prostate Cancer: Results from a Phase II Randomized Clinical Trial

ASCO 2020: Association Between BRCA2 Status and Histologic Variants Intraductal and Cribriform Histology in Prostate Cancer

ASCO 2020: Clinical Outcomes and Markers of Treatment Response in a Randomized Phase II Study of Androgen Deprivation Therapy with or Without Palbociclib in RB-Intact Metastatic Hormone-Sensitive Prostate Cancer

ASCO 2020: JAVELIN Bladder 100 Phase III Results: Maintenance Avelumab + Best Supportive Care vs BSC Alone After Platinum-Based First-Line Chemotherapy in Advanced Urothelial Carcinoma

ASCO 2020: Discussant: Promising Therapeutic Targets in Prostate Cancer

ASCO 2020: A 13-Years Follow-up Analysis of a Phase III Trial Cohort: Late Toxicities and Recurrences in Patients with Clinical Stage I Nonseminomatous Germ Cell Tumor After One Cycle of Adjuvant BEP Versus Primary Retroperitoneal Lymph Node Dissection

ASCO 2020: Overall Survival Results of Phase III ARAMIS Study of Darolutamide Added to Androgen Deprivation Therapy for Non-metastatic Castration-Resistant Prostate Cancer

ASCO 2020: DUTRENEO Trial: A Randomized Phase II Trial of DUrvalumab and TREmelimumab Versus Chemotherapy as a NEOadjuvant Approach to Muscle-Invasive Urothelial Bladder Cancer Patients Prospectively Selected by an Interferon-Gamma Immune Signature

ASCO 2020: Cost-Effectiveness of Novel Antiandrogens for Treatment of Nonmetastatic Castrate-Resistant Prostate Cancer

ASCO 2020: Discussant: Advanced Prostate Cancer: Putting Survival Into Perspective

ASCO 2020: Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study: A Canadian Cancer Trials Group Phase 2 Umbrella Trial for MCRPC (IND223/IND224)

ASCO 2020: Late Toxicities and Recurrences in Patients with Clinical Stage 1 Nonseminomatous Germ Cell Tumor After 1 Cycle of Adjuvant BEP vs. Primary Retroperitoneal Lymph Node Dissection – a 13 Years Follow-up Analysis of a Phase 3 Trial Cohort

1
2
3
4
5
6
7